Biogen Inc (NASDAQ: BIIB) has reported E.P.S. of $2.67 for its third fiscal quarter (ending September 30) versus $-0.47 for the same period a year ago — a decline of -668%. For the latest four quarters through September 30, E.P.S. were $11.10 versus $10.12 for the same period a year ago — an increase of 10%.
Recent Price Action
Biogen Inc (NASDAQ: BIIB) stock declined modestly by -1.2% on 10/30/24. The stock closed at $181.18. Moreover, this decline was accompanied by above average trading volume at 143% of normal. The stock has declined -2.5% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, BIIB is expected to continue to be a major Value Builder.
Biogen has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Biogen has a slightly positive Appreciation Score of 66 but a slightly negative Power Rating of 30, triggering the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment